focus -WSS

focus

author：focus 2025-08-26 10:55:49 - browse：4417

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Eli Lilly to acquire Versanis in heated race for weight loss drugs

focus

WSS

How faith leaders like me can help address America's obesity epidemic

Curing rare childhood diseases will falter unless Congress steps up

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Europe sees delivery challenges ahead on Alzheimer's therapies

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Medical device trials still don't enroll enough women, study finds

explore

focus

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Does aspartame cause cancer? What new WHO guidance says

Tori Bowie and the unacceptable rates of Black maternal death

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Guidelines to prevent youth baseball injuries need more muscle

Health care court cases: Humana, Sutter, Novant

Virginia high school admissions case could be legal follow

J&J expands global access to TB drug amid advocacy campaign

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How faith leaders like me can help address America's obesity epidemic

hotspot

5 takeaways from STAT's examination of Zynex Medical

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Who gets to use the title 'doctor'?

Congress likely to miss an opportunity to fix drug shortages issue

leisure time

focus

focus

Wikipedia